《即日市評》恆指失守250天均線 科指「六連跌」累挫一成
市場關注中美關係、美國債務上限等發展,受科網及金融股拖累下,恆指今日向下失守250天平均線(約19,730點)。美國第一共和銀行首季存款減少40%較預期差,美股道指及納指隔晚分別升0.2%及跌0.3%;執筆之時,美國10年期債券孳息率跌至3.447釐,美匯指數跌至101.43,道指期貨最新跌129點或0.38%,納指期貨最新跌0.42%。上證綜指今日跌10點或0.3%收3,264點,深證成指跌1.5%,滬深兩市成交額共1.13萬億人民幣。
恆指今早低開56點後跌幅擴大,午後曾跌432點一度低見19,527點,全日跌342點或1.7%,收19,617點,連跌三日(累跌779點或3.8%);國指跌131點或2%,收6,601點;恆生科技指數全日跌137點或3.5%,收3,824點,六連跌(累跌429.點或10.1%)。大市全日成交總額1,066.57億元,滬、深港通南下交易淨流入20.51億及14.51億元人民幣。中移動(00941.HK)逆市上升近0.9%,中信銀行(00998.HK)漲近3.4%。
【科指「六連跌」 京東創新低】
科網股受壓,騰訊(00700.HK)全日股價跌1.9%收338.4元,阿里巴巴(09988.HK)及美團(03690.HK)股價各下滑3.2%及近4.4%,京東(09618.HK)盤中曾低見131.6元創新低,全日跌4.1%收132.7元。晶片股受壓,中芯(00981.HK)挫近5.7%。
第一上海發表第二季策略報告指,考慮到內地經濟逐步復甦改善,國企估值迎來重估良機,以及人民幣櫃檯交易的推出,認爲今年恆生指數合理區間爲19,000至23,000點,對應今年預期市盈率爲9至11倍。該行指,港股仍處於低估值位置,在美聯儲加息環境下,高股息率具有一定的吸引力,且人民幣雙櫃檯的推出,料吸引香港離岸市場萬億人民幣資金以人民幣計價買入港股的機會。而港股現時估值橫向對比其他市場仍具有一定的安全邊際。
【跌股千三隻 醫藥股造淡】
港股主板市寬轉弱,主板股票的升跌比率爲8比31(上日爲15比25),下跌股份1,355只(跌幅3%);恆指成份股今日9只股份上升,下跌股份66只,升跌比率爲12比87(上日爲17比80)。大市今日錄沽空199.31億元,佔可沽空股份成交額907.08億元的約21.973%(上日爲24.93%)。
醫藥股受壓,石藥(01093.HK)及中生製藥(01177.HK)跌4.8%至5.6%,復星醫藥(02196.HK)跌6.4%,藥明康德(02359.HK)跌11.1%,同系藥明生物(02269.HK)挫7.1%是表現最差藍籌。
瑞銀髮表報告指,醫藥股近期調整因市場氣氛欠佳,投資者普遍對藥房股持有負面的短期看法,並預期未來幾季積極催化劑有限。醫藥股目前遠期市盈率已接近嚴控疫情期間的低位水平,意味着當盈利增長正常化時,將有很大的重估空間,進一步下跌的空間非常有限。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.